Clene Provides Update On Its NIH-Funded Expanded Access Program For CNM-Au8® In ALS (ACT-EAP)
Source: menafn.com
Rob Etherington News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rob Etherington. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rob Etherington Today - Breaking & Trending Today
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label extension
Source: eagletribune.com
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference. Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will participate in the presentatio
Source: yahoo.com
Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
CNM-Au8® treatment demonstrated significantly reduced plasma neurofilament light chain levels compared to placebo at 24 weeks Clene plans to discuss the totality of the survival and time-to-event... | June 16, 2023
Source: marketscreener.com